

## DAFTAR PUSTAKA

- Adeloye D, Chan KY, Rudan I et al (2013) An estimate of asthma prevalence in Africa: a systematic analysis. *Croat Med J* Dec 54(6):519–531
- Akhabir L. and Sanford A (2011). Genome-wide association studies for discovery of genes involved in asthma. *Respirology* 16: 396-406.
- Akinbami L (2011). Asthma Prevalence, Health Care Use, and Mortality: United States. *National Health Statistics Reports* 32: 1-15.
- Amina Hamed, Abdul Ghani, Abdul Kareem, Jasim Mohammad. The Predictive Value of IgE as Biomarker in Asthma. *Journal of Asthma*, 45:654–663, 2008
- Ammarin Thakkinstian, Mark McEvoy, Cosetta Minelli, Peter Gibson, Bob Hancox, David Duffy, John Thompson, Ian Hall, Joel Kaufman, Ting-Fan Leung, Peter Joseph Helms, Hakon Hakonarson, Eva Halpi, Ruth Navon, John Attia. Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a review. *m J Epidemiol* 2005 1;162(3):201-11
- Ana Carolina Zimiani, Fernando Augusto de Lima Marson, José Dirceu Ribeiro, Carmen Sílvia Bertuzzo. de Paiva et al. Asthma: Gln27Glu and Arg16Gly polymorphisms of the beta2-adrenergic receptor gene as risk factors *Allergy, Asthma & Clinical Immunology* 2014, 10:8
- Bakhireva LN, Schatz M, Jones KL, Chambers CD (2008) Asthma kontrol during pregnancy and the risk of pretermdelivery or impaired fetal growth. *Ann Allergy Asthma Immunol* 101(2):137–143
- Barman R, MT Alam, MMSU Islam, AM Hossain<sup>4</sup>, SAM Ahmed, SA Fattah, M yusuf Ali. Treating Asthma in Pregnancy - An Update. *Faridpur Med. Coll. J.* 2013;8(2):85-91
- Belanger K, Hellenbrand ME, Holford TR, Bracken M (2010) Effect of pregnancy on maternal asthma symptoms and medication use. *Obstet Gynecol* 115(3):559–567
- Benessiano J, Crestani B, Mestari F, Klouche W, Neukirch F, et al (1997). High frequency of a deletion polymorphism of the angiotensin-converting enzyme gene in asthma. *J Allergy Clin Immunol* 99: 53-57.

- Birbian N, Jagtar Singh, Surinder Kumar Jindal. Association of  $\beta_2$ -Adrenergic Receptor Polymorphisms with Asthma in a North Indian Population. *Lung* (2012) 190:497–504
- Boraa E, Soylerc R, Ayyıldız A, Uzunerb N, Giray O, Bozkayac, et al (2013). Plasminogen activator inhibitor-1 and angiotensin converting enzyme gene polymorphisms in Turkish asthmatic children. *Allergol Immunopathol* 41: 11-16.
- Bracken M, Belanger K, W. Cookson (2003). Genetic and Perinatal Risk Factors for Asthma Onset and Severity: A review and Theoretical analysis. *Epidemiologic Reviews* 24: 176-189.
- Bučkova, D., L. I. o. Holla and J. Va'cha (2002). Polymorphism 4G/5G in the plasminogen activator inhibitor-1 (PAI-1) gene is associated with IgE-mediated allergic diseases and asthma in the Czech population. *Allergy* 57: 446-448.
- Burhan E, Isbaniah F, Sitompul P dkk. Pedoman Pencegahan dan Pengendalian Corona Virus Disease (Covid 19), Departemen Kesehatan 2020, Revisi 5: 1-214
- Chagani T, Paré PD, Zhu S, Weir TD, Bai TR, Behbehani NA, FitzGeraldJM, Sandford AJ. (1999). Prevalence of tumor necrosis factor and angiotensin converting enzyme polymorphisms in mild/moderate and fatal/near-fatal asthma. *Am J Respir Crit Care Med* 160: 278–282
- Christopher Carroll, Petronella Stoltz Craig M, Schramm.  $\beta_2$ -Adrenergic Receptor Polymorphisms Affect Response to Treatment in Children With Severe Asthma Exacerbations. *Chest* 2009. 135;5: 1186-1192.
- Clark, T., C. Cagnani, J. Bousquet and W. Busse (2002). Global Strategy for Asthma Management and Prevention. *National Institute of Health. National Heart, Lung and Blood In health (NIH) Publication*: 1-192.
- Cho, S., o. Kang, C. Lyttle, K. Harris, B. Brendan Daley, et al (2011). Association of elevated plasminogen activator inhibitor 1 levels with diminished lung function in patients with asthma. *Ann Allergy Asthma Immunol* 106: 371-377.
- Cookson H, Granell R, Joinson C et al (2009) Mothers' anxiety during pregnancy is associated with asthma in their children. *J Allergy Clin Immunol* 123(4):847–853, e11

- Cosan D, Kurt E, Kurt H, Degirmenci I, Kucukarabaci B, Metintas M, et al. (2009) Plasminogen activator inhibitor type-1 gene 4G/5G polymorphism in Turkish adult patients with asthma. *Genet Test Mol Biomarkers* 13:543-546
- Dahlan Z, Soeroto A, Amin Z (2012). Tatalaksana Penyakit Respirasi dan Kritis Paru. *PERPARI* 2: 7-20
- Ding Q, Sun S, Cao C, Deng (2012). Association between Angiotensin-Converting Enzyme I/D Polymorphism and Asthma Risk: A Meta-Analysis Involving 11,897 Subjects. *J Asthma* 49: 557–562
- El-Sayed Z, El-Hakim I, El-Kerdani T, Ghanem H (2004). Serum transforming growth factor-beta1 in asthmatic children. *Egypt J Pediatr Allergy Immunol* 2(1): 46-51.
- El-Shafei, M., M. Farres and R. Shahin (2012). Evaluation of angiotensin converting enzyme gene polymorphism and susceptibility to bronchial asthma among Egyptians. *Allergol Immunopathol* 5: 275-280.
- Eryüksel E, C. B., Bircan R, Avşar M, Cirakoğlu B (2009). Angiotensin converting enzyme gene polymorphism in Turkish asthmatic patients. *J Asthma* 46: 335-338.
- Ensaf A, Ashraf E, Enas A. Tantawy, Elsayd M (2014). Serum levels of Interleukin-33 and its soluble receptor ST2 in asthmatic patients. *Egypt Jour Chest*. 279-284
- Gaga M, E. Oikonomidou, E. Zervas. Asthma and pregnancy: interactions and management. *Breathe* March 2007 Volume 3; 3: 267
- Gang Wang, Vanessa E. Murphy, Jennifer Namazy, Heather Powell, Michael Schatz, Christina Chambers, John Attia & Peter G. Gibson. The risk of maternal and placental complications in pregnant women with asthma: a systematic review and meta-analysis. *J Matern Fetal Neonatal Med*, 2014; 27(9): 934–942
- GINA (Global Initiative for Asthma) (2014). Global Strategy for Asthma Management and Prevention. *National Institute of Health. National Heart, Lung and Blood In health (NIH) Publication*:1-124.
- Global Strategy for Asthma Management and Prevention (GINA). updated 2021. Reddel HK, Bacharier RL, Bateman ED, et al. Asthma. Accessed [www.ginasthma.org](http://www.ginasthma.org); 1-181

- Hall IP. Beta2-adrenoceptor polymorphisms and asthma. *Clin Exp Allergy* 1999;29: 1151–1154
- Hardy-Fairbanks AJ, Baker ER (2010) Asthma in pregnancy: pathophysiology, diagnosis and management. *Obstet Gynecol Clin North Am* 37(2):159–172
- Hussein A, Suzan S. Sayed, Heba M, et all. Beta 2 Adrenergic Receptor Genetic Polymorphisms in Bronchial Asthma: Relationship to Disease Risk, Severity, and Treatment Response. *Lung* 2018; 1-7
- Hoekstra T, Geleijnse J, Cornelis K, Giltay E, Kok F, Schouten E. 4G/4G Genotype of PAI-1 Gene Is Associated with Reduced Risk of Stroke in Elderly. *Stroke AHA Jour.* 2003;34: 2822-2829
- Ingrid Granne, Jennifer H. Southcombe, James V. Snider, Dionne S. Tannetta, Tim Child, Christopher W. G. Redman, and Ian L. Sargent. ST2 and IL-33 in Pregnancy and Pre-Eclampsia. *PLoS One.* 2011; 6(9): e24463.
- Isabella Pali-Schol, Cassim Motala, Erika Jensen-Jarolim. Asthma and Allergic Diseases in Pregnancy. *WAO Journal & March* 2009 26-36.
- Israel, E., V. Chincilli, J. Ford, H. Boushey, R. Cherniack, et al (2004). Use of Regulatory Scheduled Albuterol Treatment in Asthma: genotype stratified: randomized, placebo-controlled cross-over trial. *Lancet* 364: 1505-1512.
- Keisuke O, S. N., 2 Kenji, 1 Hirohisa (2011). IL-33 and Airway Inflammation. *Allergy Asthma Immunol Res* 3: 81-88.
- Kittipong Maneechotesuwan , Pimtira Sujaritwongsanon, Tasneeya Suthamsmai. IgE production in allergic asthmatic patients with different asthma kontrol status. *J Med Assoc Thai* 2010 Jan;93 Suppl 1: 71-8.
- Lee M. Perry, Dennis R. Ownby, Ganesa R. Differences in total and allergen-specific IgE during pregnancy compared to 1 month and 1 year postpartum. *Ann Allergy Asthma Immunol.* 2009; 103(4): 342–347
- Liggett SB (2000) The pharmacogenetics of  $\beta$ 2-adrenergic receptors: relevance to asthma. *J Allergy Clin Immunol* 105:487–492.
- Lilla Tama'si, Ildiko' Horva'th, Aniko' Boha'cs, Veronika Mu'ller, Gyo'rgy Losonczy, Michael Schatz. Asthma in pregnancy e Immunological changes and clinical management. *Respiratory Medicine* (2011) 105, 159-164

- Manuyakon W., W. Kamchaisatian, K. Atamasirikul, C. Sasisakulporn (2008). Serum TGF- $\beta$ 1 in Atopikk Asthma. *Asian Pacific J Allergy Immunol* 26: 185-189.
- Mari Kempainen, Anna-Maria Lahesmaa-Korpinen, Paula Kauppi, Martti Virtanen, Suvi M. Virtanen, Riitta Karikoski, Mika Gissler, Turkk Kirjavaine, Maternal asthma is associated with increased risk of perinatal mortality. *Plos Global Public Health* J; 2018; 1-5
- Mckay, S., D. Jaongste, R. Pramod S. (1998) Angiotensin II Induces Hypertrophy of Human Airway Smooth Muscle Cells: Expression of Transcription Factors and Transforming Growht Factor betha-1. *Am J Respir Cell Mol Biol* 18: 823-833.
- Merih O, Fulya D, Ahu S, Onur A, Hasan V, Gunes I (2012). Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women. *Clinics*: 1299-1302.
- Merih Ozgen, II Fulya Doganer, Ahu Soyocak, Onur Armagan, Hasan Veysi Gunes. Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women. *Clinics* 2012: 1299-1302.
- Miller M, Cho JY, McElwain K, et al (2006). Corticosteroids prevent myofibroblast accumulation and airway remodeling in mice. *Am J Physiol Lung Cell Mol Physiol* 290: 162-169.
- Miller A (2011). Role of IL-33 in inflammation and disease. *Inflammation* 8: 1-12.
- Midodzi WK, Rowe BH, Majaesic CM et al (2010) Early life factors associated with incidence of physician-diagnosed asthma in preschool children: results from the Canadian Early Childhood Development cohort study. *J Asthma* 47(1):7–13
- Murphy VE, Clifton VL, Gibson PG (2006) Asthma exacerbations during pregnancy: incidence and association with adverse pregnancy outcomes. *Thorax* 61(2):169–176
- Murphy VE, Gibson PG, Giles WB, et al. Maternal asthma is associated with reduced female fetal growth. *Am J Respir Crit Care Med* 2003; 168: 1317–1323.
- Namazy JA, Schatz M. Pharmacotherapy options to treat asthma during pregnancy. *Expert Opin Pharmacother.* 2015;16(12):1783–91.

- NAEPP expert panel report (2005) Managing asthma during pregnancy: recommendations for pharmacologic treatment—2004 update. *J Allergy Clin Immunol* 115(1):34–46
- Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma kontrol test: A survey for assessing asthma kontrol. *J Allergy Clin Immunol* 2004 (113): 59-65; Schatz M, Sorkness CA, Li JT, Marcus P, Murray JJ, Nathan RA, Kosinski M, Pendergraft TB, Jhingran P. Asthma Kontrol Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. *J Allergy Clin Immunol* 2006; 117:549-56.
- Nicola Scichilone M, Chiara Caponetto, Evelina Fagone, Alida Benfante, Alessandra Paternò, Enrico Heffler. The Arg/Arg polymorphism of the ADRB2 is associated with the severity of allergic asthma. *J Allergy Clin Immunol Pract Month*. 2016
- Pampuch A, Kowal K, Bodzenta A, Castelnuovo D, Chyczewski L (2006). The -675 4G/5G plasminogen activator inhibitor-1 promoter polymorphism in house dust mite-sensitive allergic asthma patients. *Allergy* 61: 234-238.
- [PDPI] *Perhimpunan Dokter Paru Indonesia* (2012). Pedoman Diagnosis & Penatalaksanaan Asma Di Indonesia: 1-99.
- Préfontaine D, Nadigel J, Chouiali F, Audusseau S, Semlali A, Chakir J, Martin JG Hamid Q (2010). Increased IL-33 expression by epithelial cells in bronchial asthma. *J Allergy Clin Immunol*. 125(3):752-754
- [PERPARI] *Perhimpunan Respiriologi Makassar* (2014). Survey Penanganan Asma para Dokter Di Makassar.
- Pellegrino R, Viegi G, Brusasco V (2005). Interpretative strategies for lung function tests. *Eur Respir J* 26: 948-968.
- Rengganis I. Diagnosis dan Tatalaksana Asma Bronkial. *Majalah kedokteran Indonesia*. 2010 Volume 58(11).
- Rebordosa, M. Kogevinas, S. Guerra, F. Castro-Giner, D. Jarvis, L. Cazzoletti, I. Pin, V. Siroux, M. Wjst, J.M. Anto`, R. de Marco, X. Estivill, A.G. Corsico, R. Nielsen and C. Janson. ADRB2 Gly16Arg polymorphism, asthma control and lung function decline. *Eur Respir J* 2011; 38: 1029–1035
- Rigat B, Hubert C, Corvol P (1992). PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase). *Nucleic Acids Res* 20: 1433.

- Robert A, Nathan M, Christine A, Sarkness C, Kosinski M, Schatz M (2003). Development of the Asthma Kontrol Test: A Survey for assessing asthma kontrol. *Asthma, Allergy Associates and Research Center*. School of Pharmacy, University of Wisconsin
- Rui Li, Gang Yang, Ruiqi Yang, Xiaoxing Peng, Jing Li. Interleukin-33 and receptor ST2 as indicators in patients with asthma: a meta-analysis. *Int J Clin Exp Med* 2015;8(9):14935-14943
- Sakai, H, Nishizawa Y, Nishimura A, Chiba K (2010). Angiotensin II induces hyperresponsiveness of bronchial smooth muscle via an activation of p42/44 ERK in rats. *Pflugers Arch* 460: 645-655.
- Seong, H, H. Cho, P IanHal, A. Wheatley, b. J. Dewar (2001). Possible role of the 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene in the development of asthma. *J Allergy Clin Immunol* 108: 212-214.
- Seong H, Cho H, Sun W, Sossiena D, Scott A (2000). Production of Plasminogen Activator Inhibitor-1 by Human Mast Cells and Its Possible Role in Asthma1. *J Immunol* 165: 3154–3161.
- Seong H, Cho H, Oh C (2004). Plasminogen Activator Inhibitor-1 in the Pathogenesis of Asthma. *Exp Biol Med* 229: 138-146.
- Shahane G, Parsania C, Sengupta D, Joshi M. Molecular insights into the dynamics of pharmacogenetically important N-terminal variants of the human b2-adrenergic receptor. *PLoS Comput Biol*. 2014;10: 12-16
- Sheniz A, Moonie A, David A, Sterling F, Mario C (2006). Asthma Status and Severity Affects Missed School Days. *J Sci Health* 76: 18-24.
- Syamsu. Epidemiologi. Di dalam: Seluk Beluk Asma. Subbagian Alergi Immunologi Bagian Ilmu penyakit Dalam FK Unhas 2014: 21-22.
- Syamsu, Irawan Yusuf, Budu, Ilhamjaya Patellongi. The Effect of Polymorphysm of The  $\beta$ -2 Adrenergic Receptor on The Response to  $\beta$ -2 Agonist in Bronchial Asthma Patients. *Acta Med Indones-Indones J Intern* 2007;39(1):8-12
- Tan KS, Lesley C, McFarlane HNC<sup>a</sup>, Brian J, Lipworth MD<sup>a</sup>. Paradoxical Down-Regulation and Desensitization of  $\beta$ <sub>2</sub>-Adrenoceptors by Exogenous Progesterone in Female Asthmatics. *Chest* Volume 111, Issue 4, April 1997, Pages 847-85

- Tantisira K, Lake S, Silverman E, Palmer L, Lazarus R (2006). Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. *Human Mol Genetics* 13: 1353-1359.
- Tamasi L, Bohacs A, Pallinger E, et al. Increased interferon-gamma and interleukin-4-synthesizing subsets of circulating T lymphocytes in pregnant asthmatics. *Clin Exp Allergy* 2005; 35:1197–203.
- Thomas A. The Role of Immunoglobulin E in Allergy and Asthma. *American Jour Crit Care Med* 2001;1-7
- Vatti RR, Teuber SS. (2012) asthma and pregnancy. *Clinic Rev Immunol*; 43:45-46.
- Wang G, Murphy VE, Namazy J, Powell H, Schatz M, Chambers C, et al. The risk of maternal and placental complications in pregnant women with asthma: a systematic review and meta-analysis. *J Matern Fetal Neonatal Med.* 2014;27(9):934–42
- Wen FQ, Kohyama T, Sköld CM (2003). Glucocorticoids modulate TGF-beta production by human fetal lung fibroblasts. *Inflammation*; 27; 1 :9-19
- Wibowo N, Mose J, Chalid M dkk. Diagnosis dan Tatalaksana Pre-eklamsia. *Pedoman Nasional Pelayanan Kedokteran. POGI Himpunan Kedokteran Maternal* 2016;1-59.
- Woszczek G, M. Borowiec, A. Ptasinska, S. Kosinski, R. Pawliczak, M. L. Kowalski. b2-ADR haplotypes/polymorphisms associate with bronchodilator response and total IgE in grass allergy. *Allergy* 2005: 60: 1412–1417



# LAMPIRAN



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN  
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN  
KOMITE ETIK PENELITIAN KESEHATAN  
RSPTN UNIVERSITAS HASANUDDIN  
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR  
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu  
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.  
Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103. Fax : 0411-581431





### REKOMENDASI PERSETUJUAN ETIK

Nomor : 788/UN4.6.4.5.31/ PP36/ 2020

Tanggal: 1 Desember 2020

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH20080424	No Sponsor Protokol	
Peneliti Utama	<b>dr. Dewi Setiawati, SpOG</b>	Sponsor	
Judul Peneliti	HUBUNGAN VARIASI GEN Arg16Gly DAN Gln27Glu $\beta$ -2 ADRENERGIK RESEPTOR DENGAN KEJADIAN DAN DERAJAT KONTROL ASMA PADA KEHAMILAN		
No Versi Protokol	2	Tanggal Versi	26 November 2020
No Versi PSP	2	Tanggal Versi	26 November 2020
Tempat Penelitian	<b>Klinik Pratama Wirahusada dan Puskesmas di Kota Makassar</b>		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku <b>1 Desember 2020</b> sampai <b>1 Desember 2021</b>	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama <b>Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)</b>	Tanda tangan 	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama <b>dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)</b>	Tanda tangan 	

**Kewajiban Peneliti Utama:**

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

## **BIODATA PENELITI UTAMA**

Nama : Dewi Setiawati  
Tempat/tanggal lahir : Ujung Pandang, 21 Juni  
1981 Agama : Islam  
Instansi : Bagian Ilmu Obstetri dan Ginekologi  
NIP : 198106212006042005  
Pekerjaan : Staf Pengajar Fakultas Kedokteran dan Ilmu Kesehatan Universitas Islam Alauddin Makassar  
Status : Menikah  
    a. Nama Suami: M. Harun Iskandar  
    b. Nama Anak : 1. Aura Rahmalyah Harun  
                  2. Muhammad Rahadi Harun  
                  3. Aisyah Misyari Harun  
                  4. Alisha Qanita Harun  
Alamat Rumah : Jl. Monumen Emmy Saelan No 2 Makassar

### **Riwayat Pendidikan**

1. 1986 – 1992                   SD Negeri 80 Lalebbata Palopo
2. 1992 – 1995                 SMPN 1 Palopo
3. 1995 – 1998                 SMUN 1 Makassar
4. 1998 – 2002                Pendidikan Dokter (strata 1)
5. 2002 – 2004                 Pendidikan Dokter Klinik (koas)
6. 2008 – 2013                 Pendidikan COMBINE DEGREE UNHAS  
(Dokter Spesialis Kandungan dan Kebidanan UNHAS dan Program magister kesehatan UNHAS)

## **Riwayat Pekerjaan/Jabatan**

1. 2006 - Sekarang Dosen Fakultas Kedokteran Dan Ilmu Kesehatan UIN Alauddin Makassar
2. 2013 - Sekarang Dokter Spesialis Kandungan Dan Kebidanan RSIA St Khadijah 1 Makassar
3. 2016 - Sekarang Direktur Klinik Wirahusada Medical Center Makassar
4. 2016 - Sekarang Dokter Spesialis Kandungan Dan Kebidanan Wirahusada Medical Centre
5. 2017 - Sekarang Dokter Spesialis Kandungan Dan Kebidanan RSIA Paramount
6. 2018 - 2019 Ketua Prodi Profesi Kedokteran UIN Alauddin Makassar

## **Organisasi**

- Ikatan Dokter Indonesia (IDI)
- Perkumpulan Obstetri dan Ginekologi Indonesia

## **Kursus dan Pelatihan yang Telah Diikuti:**

1. Pelatihan Obstetri Emergensi Dasar, 2009
2. Pelatihan Laparaskopi Dasar, Bali, 2010
3. Pelatihan Kolposkopi, Makassar, 2011
4. Workshop Of Colposcopy And Manahement Of Precancer Lesio Of The Cervix And Cervical Cancer, Makassar, 2011
5. Seminar Deteksi Dini Kanker Serviks, Makassar, 2012
6. Kongres Obstetri Dan Ginekolgi Indonesia, Bali, 2012
7. Pit Pogi 20, Medan, 2013
8. Rumah Bersalin & Balai Pengobatan Wihdatul Umma, Makassar, 2013
9. Perkumpulan Obstetri & Ginekologi Indonesia Cabang Makassar (Pogi), Makassar 2013
10. Seminar Nasional Kesehatan, Makassar, 2014
11. Abosiasi Institusi Pendidikan Kedokteran Indonesia, Makassar, 2014
12. 2nd Jakarta Infertility Update, Jakarta, 2014

13. Seminar Nasional Kesehatan 2015 Yayasan Educare Institute Indonesia Kerja Sama Akbid Minasa Upa Sk. Menteri Hukum Dan Ham R.I Yayasan Educare , Makassar 2015
14. Kongres Obstetri Dan Ginekologi Indonesia XVI, Bandung 2015
15. Seminar Kolaborasi Nasional Kesehatan & Workshop Kegawatdaruratan Departemen Obsteri Dan Ginekologi Fakultas Kedokteran Universitas Padjajaran Rs Dr. Hasan Sadikin Bandung, 2016
16. International Seminar & Workshop World Aids Day, Makassar, 2017
17. Simposium makassar obstetrics & gynecology updates Makassar, 2018
18. Kongres Obstetri Ginekologi Indonesia XVII, 2018
19. Preeklampsia dan fertility update. Kuala lumpur. 2018
20. Workshop Preeklamsi & PJT, 2019
21. Prince Court Medical Center, Kuala Lumpur 2019
22. Pertemuan Ilmiah Tahunan POGI, Surabaya 2019
23. Seminar & Workshop Nasional Kesehatan "Prevention and Manajement HIV AIDS – Stop Discrimination ODHA"- UNHAS, 2019
24. One Day Symposium – Female Genital Cosmetic Surgery : Prime Plaza Hotel Sanur, January 11, 2020
25. SIMPOSIUM, PIT Kedokteran Fetomaternal XXI Surabaya, 16-18 Maret 2020
26. Peran progesteron untuk kesehatan reproduksi perempuan; semarang, 8 agustus 2020
27. Integrated approach in optimizing the first 1000 days of life during Covid- 19 pandemic, 8 agustus 2020
28. Role Of Cryoablation/cryosurgery in breast & lung cancer treatment, 10 september 2020
29. IN-ALARM has demonstrated advanced in intrapartumm obstetrics as a participant, Surabaya 05-07 oktober 2020
30. Investigating the Effectiveness of Scar-management Modalities, Jakarta 24 Januari 2021
31. The 9<sup>th</sup> Jakarta International chest and critical care internal medicine, Jakarta 29-30 Mei, 5-6 juni, 12-13 juni 2021
32. POGI Kalimantan Timur 202, 17 April 2021
33. 4<sup>th</sup> Medan obgyn update (MOU) Webinar pogi cabang sumatera utara "Biologically Active Form of Folate : Is It Needed?", Medan 4 Sep 2021

### **Presentasi Ilmiah:**

1. *Penyuluhan dan Pemeriksaan Kesehatan : SADARI, Basic Life Support dan Status Gizi Anak* **Dewi Setiawati**, SMA Negeri 13 Bone 2019
2. *Sembuh dari Covid-19 perspektif Kesehatan dan Islam* **Dewi Setiawati**, Program Doktor Dirasat UIN Alauddin Makassar 2019.
3. *Pencegahan dan Penanggulangan Pasien Hepatitis*, **Dewi Setiawati**, Medicare Center Indonesia dan Gerakan Peduli Hepatitis Graha Pena, 2019
4. *Deteksi dini Kanker Serviks dan Workshop Penanggulangan Gagal ginjal*, **Dewi Setiawati**, Medicare Center Indonesia Baruga AP. UNHAS 2019
5. *Inspiring Parents* **Dewi Setiawati**, TKIT Wihdatul Ummah Makassar 2020

### **Karya Ilmiah:**

1. *Human Papilloma Virus dan Kanker Serviks*. **Dewi Setiawati**, The Public Health Science Journal 6 (2), Vol 2014:19
2. *Pengaruh penyuluhan dan konseling terhadap penerapan gender terhadap pemilihan metode kontrasepsi pasangan suami istri dan pengaruhnya terhadap tingkat kepuasan seksual*. **Dewi Setiawati**, Irmawati. Jurnal Kesehatan 10 (2), 41-50 Vol 2017:1
3. *An Exploratory Study On Health Reproduction Understanding and Community Social Control Towards Pre-Marital Sex Behaviors among Adolescents In Makassar* .**Dewi Setiawati**, Hasbi Ibrahim, Habibi, Raully Rahmahani International Journal of Research in Applied, Natural and Social Sciences. Volume 7 2019:1-10.
4. *The Role Of Inflammation In Pathogenesis Of Preeclampsia : An Investigation Of Interleukin-6, Interleukin 10 and The Ratio*. **Dewi Setiawati**  
, International Journal Of Medical Reviews and Case Reports (2020) 4 (10):13-17
5. *Analisis Hubungan Preeklampsia-Eklampsia gravidarum dengan kejadian persalinan preamatur pada ibu bersalin di RSUD Prof. Dr. H. Aloei Saboe Periode januari-september Tahun 2020* **Dewi Setiawati**, Dewi meliyani

Ramadlana Sulaeman, Arlina Wiyata, Jurnal Kedokteran Vol. 06 No 02 2021

6. *High Levels of Immunoglobulin E Plasma as a Predictor of Uncontrolled Asthma in pregnancy.* **Dewi Setiawati**, Suryani as'ad, Irawaty Djaharuddin, Rahmawati Minhajat. Sapporo Medical Journal. Vol 55 (11) 2021
7. *Arg16Gly Polymorphisms of the Beta2-adrenergic Receptor Gene as Risk for Insidens and Uncontrolled Asthma in Pregnancy.* **Dewi Setiawati**, Suryani as'ad, Irawaty Djaharuddin, Rahmawati Minhajat, Mochammad Hatta, Nasruddin Mappaware, Mardiah Tahir, Yuyun Widaningsih, Armyn Nurdin, Burhanuddin Bahar, Accepted in International Medical Journal IMJ-22-11- 2021-1064

#### **Karya Buku:**

1. *Buku Saku Dasar-dasar Obstetri* : **Dewi Setiawati**, Alauddin University Press, Makassar 2011. page 133, ISBN 9786022370741
2. *Seputar Kehamilan dan persalinan* **Dewi Setiawati**, Alauddin University Press, Makassar 2013. page 288, ISBN 9786022376781
3. *Question and Answer : Seputar kehamilan dan persalinan* **Dewi Setiawati**, Alauddin University Press, Makassar 2019. page 156, ISBN 9786023282494
4. *Fisio-Patologi kehamilan, persalinan dan kasih sayang universal : Bagaimana proses setetes sperma menjadi makhluk hidup baru* **Dewi Setiawati**, Alauddin University Press, Makassar 2020. page 155, ISBN 9786023283217
5. *Soul Talk.* **Dewi Setiawati**, Alauddin University Press, Makassar 2021. page 145 ISBN 9786023283712

**HASIL PEMERIKSAAN**  
**Variasi Genetik rs1042713 dan rs1042714**  
**Sampel Penelitian dr. Dewi Setiawati, SpOG (Makassar)**

NO	No Lab	Nama	ADRS2 Arg16Gly (rs1042713)	ADRS2 Gln27Glu (rs1042714)
1	2101210089	HSB	GG	CC
2	2101210093	BL	GG	CC
3	2101210094	PT	GA	CC
4	2101210095	AHL	GA	CC
5	2101210301	RL	GA	CC
6	2101210302	E	GG	CC
7	2101210314	RR	GG	CC
8	2101210315	SW	AA	CC
9	2101230209	R	AA	CC
10	2101230211	SAB	GA	CC
11	2101230214	N	GG	CC
12	2101250337	REP	GG	CC
13	2101250340	RTA	GG	CC
14	2101250352	WR	GG	CC
15	2101250353	ATA	GA	CC
16	2101280201	MHB	GA	CC
17	2102010280	UP1	GA	CC
18	2102010282	RA	AA	CC
19	2102050247	TW	AA	CC
20	2102050248	RF	AA	CC
21	2102060232	ARR	GA	CC
22	2102080302	HR	GA	CC
23	2102200228	RTAR	GG	CC
24	2102200229	RA	GA	CC
25	2102220271	SH	AA	CC
26	2102220272	SNS	AA	CC
27	2102240165	H	AA	CC
28	2103020226	RO	GA	CC
29	2103040221	RZ	AA	CC
30	2103040222	SS	AA	CC
31	2103060238	RS	AA	CC
32	2103060242	N	GA	CC
33	2103170221	RMS	GG	CC
34	2103170225	RA.R	GA	CC
35	2103190186	AS	GG	CC
36	2103200224	LWN	GA	CC
37	2103200226	AT	GG	CC



NO	No Lab	Nama	ADRB2 Arg16Gly (rs1042713)	ADRB2 Gln27Glu (rs1042714)
38	2103220258	NH	GG	CC
39	2103250155	BW	GA	CC
40	2103290172	ANM	GA	CC
41	2103290173	R	AA	CC
42	2103300193	M	AA	CC
43	2104050269	HST	GA	GC
44	2104050270	ARRP	GA	CC
45	2104060246	DM	AA	CC
46	2104060247	S	GG	CC
47	2104060248	ADS	GA	GC
48	2104080312	AL	GA	CC
49	2104090240	HS	GA	CC
50	2104120203	RW	GA	CC
51	2104130166	H	GA	CC
52	2104170190	HS	GA	CC
53	2104170191	AS	GA	CC
54	2104220099	AAA	AA	CC
55	2104270176	NSR	AA	CC
56	2105040234	JB	GA	GC
57	2105040236	NI	GA	CC
58	2105100149	RHR	GA	CC
59	2105100150	IN	GG	CC
60	2105110127	AMS	GA	CC
61	2105110128	M	AA	CC
62	2105110130	ANM	GA	CC
63	2105170254	DAR	GA	CC
64	2105200204	NS	AA	CC
65	2105220211	H	GA	CC
66	2105220213	R	GA	CC
67	2105240250	SW	GA	CC
68	2105240251	NA	GG	CC
69	2105250245	NAN	AA	CC
70	2105270062	K	GG	GC
71	2105270220	A	GG	GC
72	2105270221	NP	AA	CC
73	2105270222	SRM	GG	CC
74	2105290151	SA	GA	GC
75	2106020216	F	GG	CC
76	2106020217	AK	AA	CC
77	2106030240	NA	AA	CC
78	2106030241	NZH	AA	CC
79	2106030242	ARM	GG	CC



**Laboratorium Riset**  
 Laboratorium Klinik Prodia  
 Jl. Kramat Raya No.150, Lt.3, Jakarta 10430  
 Telp. (021) 2961800 Ext.3710  
 Email : lab.penet@amprodia.co.id

NO	No Lab	Nama	ADRB2 Arg16Gly (rs1042713)	ADRB2 Gln27Glu (rs1042714)
80	2105040146	RI	AA	CC
81	2105100154	RI	GG	CC
82	2105200212	QA	AA	CC

**Catatan:**

- Sampel yang dipelajari adalah dari 1074.
- rs1042713 pada 30, pengulangan, haplotipe, yang dapat dipelajari pada ADRB2 -661 + G, Arg16, Gln6, (p. Arg16Gly).
- rs1042714 pada 30, pengulangan, haplotipe, yang dapat dipelajari pada ADRB2 -790 + G, G271, (p. Gln27Glu).
- Reagen, alat, dan yang dipelajari adalah: Company, QIA Mini Kit (Qiagen/Cat No. 51304), Company, Nucleo Spin, (Merck/ Sigma Co.), Merck/ Sigma Co., No. 04500, Cat. : 04500, Lot : P030801-04, ID : 30 Feb 2011 / 2021.
- Reagen dan PCR yang dipelajari adalah: Reagen Q-Solvent (Merck/ the Applied Biosystems, CA, USA) Cat no : 481111, Lot : 01002100, ID : 30 Apr 2021 / 2021.
- Analisis rs1042713 menggunakan Reagen di SNP Genotyping Assay C - 204761\_30 Applied Biosystems, CA, USA) Cat no : 481129, Lot : 01002100102, ID : 27 Apr 2021 / 2021.
- Analisis rs1042714 menggunakan Reagen di SNP Genotyping Assay C - 204761\_30 Applied Biosystems, CA, USA) Cat no : 481129, Lot : 01002100102, ID : 27 Apr 2021 / 2021.
- Reagen/ alat yang dipelajari adalah: QIA96 Nucleo Spin - PCR Spin (Merck/ CA, USA).
- Kit yang dipelajari adalah kit: Massan untuk genotipe (for research use only, not for use in diagnostic or therapeutic procedures).

Jakarta, 30 Agustus 2021

(Dr. Muzni Fadhilah, M.Si.)  
 Head of Research and Specialty Test Development

## HASIL PEMERIKSAAN

### Interleukin 33 (IL-33)

Sampel Penelitian dr. Dewi Setiawati, SpOG (Makassar)

NO	No Lab	Nama	IL-33 (pg/mL)
1	2101210089	HSB	2.30
2	2101210093	BL	1.14
3	2101210094	PT	1.42
4	2101210095	AHI	1.19
5	2101210301	M	0.82
6	2101210302	E	0.82
7	2101210314	RR	0.96
8	2101210315	SW	0.57
9	2101230209	N	3.02
10	2101230211	SRB	1.85
11	2101230214	N	1.76
12	2101250337	REP	1.42
13	2101250340	RRA	1.05
14	2101260232	KPR	1.09
15	2101260233	ARA	1.33
16	2101280201	NRB	< 0.357
17	2102010280	LFI	2.00
18	2102010282	MA	1.51
19	2102050247	TW	1.56
20	2102050248	NF	1.47
21	2102060232	ARR	1.19
22	2102080302	HR	1.09
23	2102200228	NTAR	1.33
24	2102200229	NA	0.65
25	2102220271	SH	2.71
26	2102220272	SNS	2.00
27	2102240165	H	1.90
28	2103020226	RO	1.95
29	2103040221	NZ	1.61
30	2103040222	SS	1.23
31	2103060238	RS	1.05



**Laboratorium Riset**  
 Laboratorium Klinik Prodia  
 Jl. Kramat Raya No.150, Lt.3, Jakarta 10430  
 Telp. (021) 29803800 Ext.3710  
 Email : lab.peneftikan@prodia.co.id

NO	No Lab	Nama	IL-33 (pg/mL)
32	2103060242	N	1.00
33	2103170221	NKS	2.60
34	2103170225	RAR	1.42
35	2103190186	AS	1.56
36	2103200224	UWN	1.95
37	2103200226	AT	1.76
38	2103220258	NH	1.61
39	2103250155	IKW	1.28
40	2103290172	ANH	2.00
41	2103290173	R	2.81
42	2103300193	M	2.86
43	2104050269	HST	1.85
44	2104050270	AIRF	2.20
45	2104060246	DM	1.42
46	2104060247	S	1.33
47	2104060248	ADS	1.19
48	2104090240	MS	2.92
49	2104120203	RW	2.30
50	2104130166	H	2.00
51	2104170190	HB	1.76
52	2104170191	AS	3.28
53	2104220099	AA	1.61
54	2104270176	NSR	1.37
55	2105040234	JB	1.33
56	2105040236	NI	1.28
57	2105100149	RRR	2.05
58	2105100150	IN	1.80
59	2105100154	AR	1.66
60	2105110127	AMS	1.51
61	2105110128	M	1.33
62	2105110130	ANH	5.01
63	2105170254	DAR	1.23
64	2105200204	NS	2.40
65	2105220211	H	2.05
66	2105220213	R	1.95
67	2105240250	SW	1.51



**Laboratorium Riset**  
 Laboratorium Klinik Prodia  
 Jl. Kramat Raya No.150, Lt.3, Jakarta 10430  
 Telp. (021) 29803800 Ext.3710  
 Email : lab.penelitian@prodia.co.id

NO	No Lab	Nama	IL-33 (pg/mL)
68	21052402-51	NA	1.14
69	21052502-45	NAN	1.76
70	21052700-62	K	0.96
71	21052702-20	A	1.23
72	21052702-21	NP	1.61
73	21052702-22	SRH	3.88
74	21052901-51	SA	1.66
75	21060202-16	F	1.61
76	21060202-17	AK	1.66
77	21060302-40	NA	4.78
78	21060302-41	NZM	3.18
79	21060302-42	ARM	5.18
80	21060401-46	M	0.96

**Catatan:**

- Sampel yang digunakan adalah serum.
- Reagen kit yang digunakan adalah Quantikine ELISA Human IL-33 (R&D Systems, Inc., Minneapolis, USA)  
 Cat: D3100B, Lot: P281139, ED: 28 Desember 2021
- Rentang standard kit/lot adalah 3.13 - 300 pg/mL, Limit deteksi: 0.257 pg/mL.
- Sampel dalam pada serum 20 siklus untuk: tidak terdeteksi, nilai rendah tidak terdeteksi
- Pengukuran menggunakan instrumen Microplate Reader Biorad model 680 (Bio-rad Laboratories Inc, CA, USA)  
 dengan software Microplate Manager ver 5.2.1 (Bio-rad Laboratories Inc., CA, USA).
- Kit yang digunakan adalah kit khusus untuk penelitian (for research use only, not for use in diagnostic or therapeutic procedures).

Jakarta, 23 Juli 2021

(Dr. Miswar Fattah, M.Si.)


Head of Research and Specialty Test Development



Laboratorium Riset  
 Laboratorium Klinik Prodia  
 Jl. Kramat Raya No.150, Lt.3, Jakarta 10430  
 Telp. (021) 29803800 Ext.3710  
 Email : lab.penelitian@prodia.co.id


**HASIL PEMERIKSAAN**  
**Variasi Genetik rs1042713 dan rs1042714**  
**Sampel Penelitian dr. Dewi Setiawati, SpOG (Makassar)**

**Allelic Discrimination Plot rs1042713**



No.	Fluorescence	Genotype
1	VIC	AA (■)
2	FAM	GG (●)
2	FAM dan VIC	GA (▲)

**Allelic Discrimination Plot rs1042714**



No.	Fluorescence	Genotype
1	VIC	CC (■)
2	FAM	GG (●)
2	FAM dan VIC	GC (▲)



**Laboratorium Riset**  
 Laboratorium Klinik Prodia  
 Jl. Kramat Raya No.150, Lt.3, Jakarta 10430  
 Telp. (021) 29803800 Ext.3710  
 Email : lab.penelitian@prodia.co.id

**INFORMASI TAMBAHAN**  
**Variasi Genetik rs1042713**  
**Sampel Penelitian dr. Dewi Setiawati, SpOG (Makassar)**

Nama internasional SNP : rs1042713  
 Referensi dbSNP : <https://www.ncbi.nlm.nih.gov/snp/rs1042713>  
 Nama Konvensional : ADRB2 +46A > G; Arg16; G16R; Arg 16Gly  
 Nama Lain : Archive dbSNP rs17287432, rs17334179, rs17721693, rs17839749, rs3729940, rs17859732, rs3182174, rs17334242, rs56964295, rs17846639, rs52812686  
 Konsekuensi variasi Genetik : ADRB2 : Missense Variant  
 Dampak terkait klinis (ClinVar) : benign (Terakhir ditinjau : 31 Desember 2019)  
 Prevalensi variasi Genetik : Data dari Ensembl  
 Referensi prevalensi : [http://asia.ensembl.org/Homo\\_sapiens/Variation/Population?db=core;v=5:148826377-148827377;vrs=rs1042713;vdb=variation;vf=166041816](http://asia.ensembl.org/Homo_sapiens/Variation/Population?db=core;v=5:148826377-148827377;vrs=rs1042713;vdb=variation;vf=166041816)

**Population genetics**

1000 Genomes Project Phase 3 allele frequencies



**Komparasi Prevalensi dari data Riset Ini**

Homozygote variant (GG)	22	27 %
Heterozygote (GA)	35	43 %
Homozygote variant (AA)	25	30 %
Prevalensi alel G	79	48 %
Prevalensi alel A	85	52 %





**Laboratorium Riset**  
 Laboratorium Klinik Prodia  
 Jl. Kramat Raya No.150, Lt.3, Jakarta 10430  
 Telp. (021) 29803800 Ext.3710  
 Email : lab.penelitian@prodia.co.id

## INFORMASI TAMBAHAN Variasi Genetik rs1042714

Sampel Penelitian dr. Dewi Setiawati, SpOG (Makassar)

Nama internasional SNP : rs1042714  
 Referensi dbSNP : <https://www.ncbi.nlm.nih.gov/snp/rs1042714>  
 Nama Konvensional : ADRB2 +79C > G; Q27E; Gln27 Glu  
 Nama Lain : Archive dbSNP rs17640526, rs3182175, rs3729941, rs17858183, rs17334200, rs52793394, rs17859733, rs17287474, rs17287411, rs17845338, rs60374884  
 Konsekuensi variasi Genetik : ADRB2 : Stop Gained  
 Dampak terkait klinis (ClinVar) : benign (Terakhir ditinjau : 31 Desember 2019)  
 Prevalensi variasi Genetik : Data dari Ensembl  
 Referensi prevalensi : [http://asia.ensembl.org/Homo\\_sapiens/Variation/Population?db=core;v=5:148826410-148827410;vrs=rs1042714;vdb=variation;vf=166041919#population\\_freq\\_EAS](http://asia.ensembl.org/Homo_sapiens/Variation/Population?db=core;v=5:148826410-148827410;vrs=rs1042714;vdb=variation;vf=166041919#population_freq_EAS)

### Population genetics @

1000 Genomes Project Phase 3 allele frequencies



### Komparasi Prevalensi dari data Riset Ini

Homozygote variant (CC)	64	78%
Heterozygote (GC)	17	21%
Homozygote variant (GG)	1	1%

Prevalensi alel C	145	89%
Prevalensi alel G	19	12%







KLINIK WIRAHUSADA MEDICAL CENTER  
Jl. Monumen Emmy Saelan No. 2  
Telp. 0411-883736/0821 8855 8835  
Email : [wirahusadamedicalcenter@gmail.com](mailto:wirahusadamedicalcenter@gmail.com)

**SURAT KETERANGAN SELESAI PENELITIAN**

Nomor : 017/02/KL-WMC/I/2022

Yang bertanda tangan dibawah ini Direktur SDM Klinik Wirahusada Medical Center,  
menerangkan bahwa:


Nama : Dewi Setiawati  
NIM : C013181025  
Program Studi : S3 Ilmu Kedokteran  
Institusi : Fakultas Kedokteran  
Universitas Hasanuddin Makassar  
No. HP : 08114109016

Benar telah melakukan penelitian di Klinik Wirahusada Medical Center dari bulan November 2020 - Juni 2021 dengan judul penelitian "Hubungan variasi gen  $\beta$ -2 adrenergik reseptor dengan kejadian dan derajat asma pada kehamilan Tinjauan terhadap kadar il-33, imunoglobulin e plasma, kelainan kehamilan dan kelainan janin"

Demikian surat keterangan ini dibuat untuk digunakan sebagaimana mestinya.

Januari 2022

Direktur SDM Klinik Wirahusada Medical Center

  
dr. Achmad Harun Muchsin, SpN

## Crosstabs

Arf16Gly2 \* IBUHAMIL Crosstabulation

			IBUHAMIL		Total
			ASMA GRAVID	NON ASMA GRAVID	
Arf16Gly2	AA	Count	17	8	25
		% within Arf16Gly2	68.0%	32.0%	100.0%
	AG/GG	Count	23	32	55
		% within Arf16Gly2	41.8%	58.2%	100.0%
Total		Count	40	40	80
		% within Arf16Gly2	50.0%	50.0%	100.0%

### Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	4.713 <sup>a</sup>	1	.030		
Continuity Correction <sup>b</sup>	3.724	1	.054		
Likelihood Ratio	4.793	1	.029		
Fisher's Exact Test				.053	.026
Linear-by-Linear Association	4.654	1	.031		
N of Valid Cases	80				

a. 0 cells (,0%) have expected count less than 5. The minimum expected count is 12,50.

b. Computed only for a 2x2 table

#### Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Arf16Gly2 (AA / AG/GG)	2.957	1.091	8.009
For cohort IBUHAMIL = ASMA GRAVID	1.626	1.077	2.454
For cohort IBUHAMIL = NON ASMA GRAVID	.550	.298	1.016
N of Valid Cases	80		

#### Crosstabs

##### Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Gln27Glu2 * IBUHAMIL	80	100.0%	0	0.0%	80	100.0%

## Gln27Glu2 \* IBUHAMIL Crosstabulation

			IBUHAMIL		Total
			ASMA GRAVID	NON ASMA GRAVID	
Gln27Glu2	CC	Count	34	28	62
		% within Gln27Glu2	54.8%	45.2%	100.0%
	CG/GG	Count	6	12	18
		% within Gln27Glu2	33.3%	66.7%	100.0%
Total		Count	40	40	80
		% within Gln27Glu2	50.0%	50.0%	100.0%

## Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	2.581 <sup>a</sup>	1	.108		
Continuity Correction <sup>b</sup>	1.792	1	.181		
Likelihood Ratio	2.620	1	.106		
Fisher's Exact Test				.180	.090
Linear-by-Linear Association	2.548	1	.110		
N of Valid Cases	80				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 9,00.

b. Computed only for a 2x2 table

### Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Gln27Glu2 (CC / CG/GG)	2.429	.808	7.298
For cohort IBUHAMIL = ASMA GRAVID	1.645	.824	3.284
For cohort IBUHAMIL = NON ASMA GRAVID	.677	.442	1.038
N of Valid Cases	80		

### Crosstabs

#### Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Arf16Gly2 * Asma Kontrol group	40	50.0%	40	50.0%	80	100.0%

**Arf16Gly2 \* Asma Kontrol group Crosstabulation**

			Asma Kontrol group		Total
			asma tidak terkontrol	Asma terkontrol	
Arf16Gly2	AA	Count	13	4	17
		% within Arf16Gly2	76.5%	23.5%	100.0%
	AG/GG	Count	9	14	23
		% within Arf16Gly2	39.1%	60.9%	100.0%
Total		Count	22	18	40
		% within Arf16Gly2	55.0%	45.0%	100.0%

**Chi-Square Tests**

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	5.507 <sup>a</sup>	1	.019		
Continuity Correction <sup>b</sup>	4.101	1	.043		
Likelihood Ratio	5.712	1	.017		
Fisher's Exact Test				.027	.020
Linear-by-Linear Association	5.369	1	.020		
N of Valid Cases	40				

**Risk Estimate**

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Arf16Gly2 (AA / AG/GG)	5.056	1.248	20.480
For cohort Asma Kontrol group = asma tidak terkontrol	1.954	1.101	3.469
For cohort Asma Kontrol group = Asma terkontrol	.387	.154	.968
N of Valid Cases	40		

**Crosstabs****Case Processing Summary**

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Gln27Glu2 * Asma Kontrol group	40	50.0%	40	50.0%	80	100.0%

Gln27Glu2 \* Asma Kontrol group Crosstabulation

			Asma Kontrol group		Total
			asma tidak terkontrol	Asma terkontrol	
Gln27Glu2	CC	Count	21	13	34
		% within Gln27Glu2	61.8%	38.2%	100.0%
	CG/GG	Count	1	5	6
		% within Gln27Glu2	16.7%	83.3%	100.0%
Total		Count	22	18	40
		% within Gln27Glu2	55.0%	45.0%	100.0%

## Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	4.191 <sup>a</sup>	1	.041		
Continuity Correction <sup>b</sup>	2.567	1	.109		
Likelihood Ratio	4.410	1	.036		
Fisher's Exact Test				.073	.054
Linear-by-Linear Association	4.086	1	.043		
N of Valid Cases	40				

a. 2 cells (50,0%) have expected count less than 5. The minimum expected count is 2,70.

b. Computed only for a 2x2 table



**Risk Estimate**

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Gln27Glu2 (CC / CG/GG)	8.077	.846	77.070
For cohort Asma Kontrol group = asma tidak terkontrol	3.706	.607	22.614
For cohort Asma Kontrol group = Asma terkontrol	.459	.263	.801
N of Valid Cases	40		

**T-Test****Group Statistics**

Asma Kontrol group		N	Mean	Std. Deviation	Std. Error Mean
IgE	asma tidak terkontrol	22	745.7636	801.02984	170.78014
	Asma terkontrol	18	264.6833	398.58331	93.94699
Kadar IL33	asma tidak terkontrol	22	1.6145	1.04197	.22215
	Asma terkontrol	18	1.9817	.69840	.16461

## Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means		
		F	Sig.	t	df	Sig. (2-tailed)
IgE	Equal variances assumed	6.408	.016	2.320	38	.026
	Equal variances not assumed			2.468	32.012	.019
Kadar IL33	Equal variances assumed	.607	.441	-1.277	38	.209
	Equal variances not assumed			-1.328	36.718	.192

## Independent Samples Test

		t-test for Equality of Means			
		Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
				Lower	Upper
IgE	Equal variances assumed	481.08030	207.35667	61.30867	900.85194
	Equal variances not assumed	481.08030	194.91509	84.05694	878.10366
Kadar IL33	Equal variances assumed	-.36712	.28748	-.94910	.21486
	Equal variances not assumed	-.36712	.27649	-.92749	.19325

## T-Test

### Group Statistics

IBUHAMIL		N	Mean	Std. Deviation	Std. Error Mean
IgE	ASMA GRAVID	40	529.2775	688.11580	108.80066
	NON ASMA GRAVID	40	66.7770	119.09834	18.83110
Kadar IL33	ASMA GRAVID	40	1.7798	.91183	.14417
	NON ASMA GRAVID	40	1.6060	.86916	.13743

### Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means			
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference
IgE	Equal variances assumed	28.016	.000	4.189	78	.000	462.50050
	Equal variances not assumed			4.189	41.334	.000	462.50050
Kadar IL33	Equal variances assumed	.614	.436	.872	78	.386	.17375
	Equal variances not assumed			.872	77.822	.386	.17375

### Independent Samples Test

		t-test for Equality of Means		
		Std. Error Difference	95% Confidence Interval of the Difference	
			Lower	Upper
IgE	Equal variances assumed	110.41827	242.67461	682.32639
	Equal variances not assumed	110.41827	239.56107	685.43993
Kadar IL33	Equal variances assumed	.19918	-.22278	.57028
	Equal variances not assumed	.19918	-.22280	.57030

### T-Test

#### Group Statistics

Arf16Gly2		N	Mean	Std. Deviation	Std. Error Mean
Kadar IL33	AA	25	1.8708	.97088	.19418
	AG/GG	55	1.6120	.84676	.11418
IgE	AA	25	302.5000	438.59837	87.71967
	AG/GG	55	295.9942	588.16074	79.30758

## Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means			
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference
Kadar IL33	Equal variances assumed	.680	.412	1.210	78	.230	.25880
	Equal variances not assumed			1.149	41.272	.257	.25880
IgE	Equal variances assumed	.054	.817	.049	78	.961	6.50582
	Equal variances not assumed			.055	61.121	.956	6.50582

## Independent Samples Test

		t-test for Equality of Means		
		Std. Error Difference	95% Confidence Interval of the Difference	
			Lower	Upper
Kadar IL33	Equal variances assumed	.21390	-.16705	.68465
	Equal variances not assumed	.22526	-.19602	.71362
IgE	Equal variances assumed	131.82521	-255.93802	268.94966
	Equal variances not assumed	118.25580	-229.95181	242.96345

## T-Test

### Group Statistics

Gln27Glu2		N	Mean	Std. Deviation	Std. Error Mean
Kadar IL33	CC	62	1.8185	.94610	.12016
	CG/GG	18	1.2600	.45617	.10752
IgE	CC	62	310.1803	559.49347	71.05574
	CG/GG	18	256.1667	494.81127	116.62813

### Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means			
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference
Kadar IL33	Equal variances assumed	4.149	.045	2.416	78	.018	.55855
	Equal variances not assumed			3.464	59.926	.001	.55855
IgE	Equal variances assumed	.033	.857	.369	78	.713	54.01366
	Equal variances not assumed			.396	30.781	.695	54.01366

### Independent Samples Test

		t-test for Equality of Means		
		Std. Error Difference	95% Confidence Interval of the Difference	
			Lower	Upper
Kadar IL33	Equal variances assumed	.23115	.09836	1.01874
	Equal variances not assumed	.16124	.23601	.88108
IgE	Equal variances assumed	146.19915	-237.04650	345.07381
	Equal variances not assumed	136.56881	-224.60073	332.62804

### Crosstabs

#### Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
InteraksiG * IBUHAMIL	80	100.0%	0	0.0%	80	100.0%
InteraksiG * Asma Kontrol group	40	50.0%	40	50.0%	80	100.0%

## InteraksiG \* IBUHAMIL

### Crosstab

			IBUHAMIL		Total
			ASMA GRAVID	NON ASMA GRAVID	
InteraksiG	AA,CC	Count	17	9	26
		% within InteraksiG	65.4%	34.6%	100.0%
	nonAA CC	Count	17	19	36
		% within InteraksiG	47.2%	52.8%	100.0%
	nonAA nonCC	Count	6	12	18
		% within InteraksiG	33.3%	66.7%	100.0%
Total	Count		40	40	80
	% within InteraksiG		50.0%	50.0%	100.0%

### Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	4.573 <sup>a</sup>	2	.102
Likelihood Ratio	4.652	2	.098
Linear-by-Linear Association	4.444	1	.035
N of Valid Cases	80		



## InteraksiG \* Asma Kontrol group

Crosstab

			Asma Kontrol group		Total
			asma tidak terkontrol	Asma terkontrol	
InteraksiG	AA,CC	Count	13	4	17
		% within InteraksiG	76.5%	23.5%	100.0%
	nonAA CC	Count	8	9	17
		% within InteraksiG	47.1%	52.9%	100.0%
	nonAA nonCC	Count	1	5	6
		% within InteraksiG	16.7%	83.3%	100.0%
Total	Count		22	18	40
	% within InteraksiG		55.0%	45.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	7.162 <sup>a</sup>	2	.028
Likelihood Ratio	7.586	2	.023
Linear-by-Linear Association	6.674	1	.010
N of Valid Cases	40		

a. 2 cells (33,3%) have expected count less than 5. The minimum expected count is 2,70.

**Risk Estimate**

	Value
Odds Ratio for InteraksiG (AA,CC / nonAA CC)	<sup>a</sup>

a. Risk Estimate statistics cannot be computed. They are only computed for a 2\*2 table without empty cells.

**Crosstabs****Case Processing Summary**

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Interaksi13 * IBUHAMIL	62	77.5%	18	22.5%	80	100.0%
Interaksi14 * IBUHAMIL	44	55.0%	36	45.0%	80	100.0%

## Interaksi13 \* IBUHAMIL

Crosstab

			IBUHAMIL		Total
			ASMA GRAVID	NON ASMA GRAVID	
Interaksi13	AA + CC	Count	17	9	26
		% within Interaksi13	65.4%	34.6%	100.0%
	Non AA + CC	Count	17	19	36
		% within Interaksi13	47.2%	52.8%	100.0%
Total		Count	34	28	62
		% within Interaksi13	54.8%	45.2%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	2.011 <sup>a</sup>	1	.156		
Continuity Correction <sup>b</sup>	1.344	1	.246		
Likelihood Ratio	2.032	1	.154		
Fisher's Exact Test				.200	.123
Linear-by-Linear Association	1.978	1	.160		
N of Valid Cases	62				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 11,74.

b. Computed only for a 2x2 table

**Risk Estimate**

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Interaksi13 (AA + CC / Non AA + CC)	2.111	.746	5.971
For cohort IBUHAMIL = ASMA GRAVID	1.385	.888	2.159
For cohort IBUHAMIL = NON ASMA GRAVID	.656	.356	1.210
N of Valid Cases	62		

## Interaksi14 \* IBUHAMIL

**Crosstab**

			IBUHAMIL		Total
			ASMA GRAVID	NON ASMA GRAVID	
Interaksi14	AA + CC	Count	17	9	26
		% within Interaksi14	65.4%	34.6%	100.0%
	Non AA + Non CC	Count	6	12	18
		% within Interaksi14	33.3%	66.7%	100.0%
Total		Count	23	21	44
		% within Interaksi14	52.3%	47.7%	100.0%

**Chi-Square Tests**

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	4.380 <sup>a</sup>	1	.036		
Continuity Correction <sup>b</sup>	3.189	1	.074		
Likelihood Ratio	4.450	1	.035		
Fisher's Exact Test				.065	.037
Linear-by-Linear Association	4.280	1	.039		
N of Valid Cases	44				

a. 0 cells (,0%) have expected count less than 5. The minimum expected count is 8,59.

b. Computed only for a 2x2 table

#### Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Interaksi14 (AA + CC / Non AA + Non CC)	3.778	1.061	13.453
For cohort IBUHAMIL = ASMA GRAVID	1.962	.964	3.992
For cohort IBUHAMIL = NON ASMA GRAVID	.519	.279	.966
N of Valid Cases	44		

#### Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Interaksi13 * Asma Kontrol group	34	42.5%	46	57.5%	80	100.0%
Interaksi14 * Asma Kontrol group	23	28.8%	57	71.3%	80	100.0%

### Interaksi13 \* Asma Kontrol group

**Crosstab**

			Asma Kontrol group		Total
			asma tidak terkontrol	Asma terkontrol	
Interaksi13	AA + CC	Count	13	4	17
		% within Interaksi13	76.5%	23.5%	100.0%
	Non AA + CC	Count	8	9	17
		% within Interaksi13	47.1%	52.9%	100.0%
Total	Count		21	13	34
	% within Interaksi13		61.8%	38.2%	100.0%

**Chi-Square Tests**

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	3.114 <sup>a</sup>	1	.078		
Continuity Correction <sup>b</sup>	1.993	1	.158		
Likelihood Ratio	3.176	1	.075		
Fisher's Exact Test				.157	.079
Linear-by-Linear Association	3.022	1	.082		
N of Valid Cases	34				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 6,50.

b. Computed only for a 2x2 table

#### Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Interaksi13 (AA + CC / Non AA + CC)	3.656	.840	15.913
For cohort Asma Kontrol group = asma tidak terkontrol	1.625	.920	2.871
For cohort Asma Kontrol group = Asma terkontrol	.444	.169	1.169
N of Valid Cases	34		

#### Interaksi14 \* Asma Kontrol group

#### Crosstab

			Asma Kontrol group		Total
			asma tidak terkontrol	Asma terkontrol	
Interaksi14	AA + CC	Count	13	4	17
		% within Interaksi14	76.5%	23.5%	100.0%



Non AA + Non CC	Count	1	5	6
	% within Interaksi14	16.7%	83.3%	100.0%
Total	Count	14	9	23
	% within Interaksi14	60.9%	39.1%	100.0%

### Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	6.659 <sup>a</sup>	1	.010		
Continuity Correction <sup>b</sup>	4.385	1	.036		
Likelihood Ratio	6.832	1	.009		
Fisher's Exact Test				.018	.018
Linear-by-Linear Association	6.370	1	.012		
N of Valid Cases	23				

a. 2 cells (50,0%) have expected count less than 5. The minimum expected count is 2,35.

b. Computed only for a 2x2 table

**Risk Estimate**

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Interaksi14 (AA + CC / Non AA + Non CC)	16.250	1.442	183.093
For cohort Asma Kontrol group = asma tidak terkontrol	4.588	.752	27.995
For cohort Asma Kontrol group = Asma terkontrol	.282	.112	.715
N of Valid Cases	23		

### Asma Kontrol group \* Komplbu

#### Crosstab

			Komplbu		Total
			ada komplikasi ibu	Normal	
Asma Kontrol group	asma tidak terkontrol	Count	1	21	22
		% within Asma Kontrol group	4.5%	95.5%	100.0%
	Asma terkontrol	Count	0	18	18
		% within Asma Kontrol group	0.0%	100.0%	100.0%
Total		Count	1	39	40
		% within Asma Kontrol group	2.5%	97.5%	100.0%

#### Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.839 <sup>a</sup>	1	.360		
Continuity Correction <sup>b</sup>	.000	1	1.000		
Likelihood Ratio	1.217	1	.270		
Fisher's Exact Test				1.000	.550
Linear-by-Linear Association	.818	1	.366		
N of Valid Cases	40				

a. 2 cells (50,0%) have expected count less than 5. The minimum expected count is ,45.

b. Computed only for a 2x2 table

**Risk Estimate**

	Value	95% Confidence Interval	
		Lower	Upper
For cohort Komplbu = Normal	.955	.871	1.046
N of Valid Cases	40		

## DOKUMENTASI



